MiR-1268b confers chemosensitivity in breast cancer by targeting ERBB2-mediated PI3K-AKT pathway

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Chemoresistance is a significant challenge in breast cancer treatment.
• Aberrantly expressed microRNAs (miRNAs) are implicated in tumor progression and drug resistance.
• The role of miR-1268b in cancer, particularly breast cancer, remains uninvestigated.

Purpose of the Study:

• To investigate the role of miR-1268b in breast cancer progression and chemoresistance.
• To identify the molecular targets and pathways regulated by miR-1268b.

Main Methods:

• miRNA microarray analysis and RT-qPCR to assess miR-1268b expression.
• Dual-luciferase reporter assays, Western blot, and immunocytochemistry to validate ERBB2 as a direct target.
• Analysis of downstream effectors in the ERBB2-PI3K-AKT signaling pathway.

Main Results:

• miR-1268b was significantly upregulated in chemosensitive, ERBB2-negative breast cancer tissues and cell lines.
• Overexpression of miR-1268b induced apoptosis and increased chemosensitivity in breast cancer cells.
• ERBB2 was confirmed as a direct target of miR-1268b, with downstream effects on the PI3K-AKT pathway.

Conclusions:

• miR-1268b enhances breast cancer chemosensitivity, partly by targeting ERBB2 and modulating the PI3K-AKT pathway.
• miR-1268b represents a potential therapeutic target for improving breast cancer treatment outcomes.